Longeveron (NASDAQ:LGVN) Trading Down 1.4%

Longeveron Inc. (NASDAQ:LGVN – Get Free Report) shares dropped 1.4% during trading on Monday . The company traded as low as $2.13 and last traded at $2.15. Approximately 31,330 shares were traded during trading, a decline of 72% from the average daily volume of 112,252 shares. The stock had previously closed at $2.18.

Longeveron Price Performance

The stock has a 50-day moving average price of $2.82 and a 200 day moving average price of $3.01. The firm has a market cap of $45.51 million, a price-to-earnings ratio of -2.26 and a beta of 0.54.

Get Longeveron alerts:

Longeveron (NASDAQ:LGVN – Get Free Report) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). Longeveron had a negative net margin of 2,265.19% and a negative return on equity of 109.93%. The company had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.47 million. During the same quarter last year, the firm earned ($0.27) EPS. As a group, equities research analysts predict that Longeveron Inc. will post -0.95 earnings per share for the current year.

Institutional Investors Weigh In On Longeveron

Institutional investors have recently modified their holdings of the company. Citigroup Inc. purchased a new stake in Longeveron in the 1st quarter valued at approximately $1,004,000. Vanguard Group Inc. lifted its stake in Longeveron by 17.5% in the 1st quarter. Vanguard Group Inc. now owns 115,865 shares of the company’s stock valued at $1,599,000 after buying an additional 17,229 shares in the last quarter. Gamco Investors INC. ET AL purchased a new stake in Longeveron in the 1st quarter valued at approximately $449,000. Northern Trust Corp purchased a new stake in Longeveron in the 2nd quarter valued at approximately $63,000. Finally, State Street Corp purchased a new stake in Longeveron in the 2nd quarter valued at approximately $88,000. Hedge funds and other institutional investors own 3.80% of the company’s stock.

Longeveron Company Profile

(Get Free Report)

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors.

Further Reading

• Five stocks we like better than Longeveron
• Video Game Stocks: How to Invest in Gaming
• 2 Must-Have Silicon Companies That Don’t Make Microchips
• What is the price-to-earnings growth (PEG) ratio?
• Small Caps That Have Priced In A Hard Landing For Big Upside
• The Significance of Brokerage Rankings in Stock Selection
• This May Have Ended Alibaba’s Winter, But Is It Time To Buy?

Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.